How to buy ProPhase Labs stock | $9.18

ProPhase Labs, Inc is a drug manufacturers-specialty & generic business based in the US. ProPhase Labs shares (PRPH) are listed on the NASDAQ and all prices are listed in US Dollars. ProPhase Labs employs 48 staff and has a trailing 12-month revenue of around USD$12.5 million.

How to buy shares in ProPhase Labs

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for ProPhase Labs. Find the stock by name or ticker symbol: PRPH. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until ProPhase Labs reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. At last close price of USD$9.18, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of ProPhase Labs, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of ProPhase Labs. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

ProPhase Labs share price

Use our graph to track the performance of PRPH stocks over time.

ProPhase Labs shares at a glance

• Key figures

Information last updated 2020-12-28.

Latest market close	USD$9.18
52-week range	USD$1.37 - USD$11.82
50-day moving average	USD$9.3509
200-day moving average	USD$4.8642
Wall St. target price	USD$15.55
PE ratio	N/A
Dividend yield	N/A (13.16%)
Earnings per share (TTM)	USD$-0.327

Buy ProPhase Labs shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

Is it a good time to buy ProPhase Labs stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of ProPhase Labs, Inc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

ProPhase Labs price performance over time

Historical closes compared with the close of $9.18 from 2020-12-31

1 week (2021-01-08)	-33.48%
1 month (2020-12-16)	-14.60%
3 months (2020-10-15)	67.21%
6 months (2020-07-15)	477.36%

1 year (2020-01-15)	401.64%
2 years (2019-01-15)	204.98%
3 years (2018-01-12)	285.71%
5 years (2016-01-15)	555.71%

ProPhase Labs financials

Revenue TTM	USD$12.5 million
Gross profit TTM	USD$2.6 million
Return on assets TTM	-5.78%
Return on equity TTM	-13.79%
Profit margin	-12.92%
Book value	$0.927
Market capitalisation	USD$125.6 million

TTM: trailing 12 months

Shorting ProPhase Labs shares

There are currently 123,015 ProPhase Labs shares held short by investors – that's known as ProPhase Labs's "short interest". This figure is 9.7% down from 136,285 last month.

There are a few different ways that this level of interest in shorting ProPhase Labs shares can be evaluated.

ProPhase Labs's "short interest ratio" (SIR)

ProPhase Labs's "short interest ratio" (SIR) is the quantity of ProPhase Labs shares currently shorted divided by the average quantity of ProPhase Labs shares traded daily (recently around 61816.582914573). ProPhase Labs's SIR currently stands at 1.99. In other words for every 100,000 ProPhase Labs shares traded daily on the market, roughly 1990 shares are currently held short.

However ProPhase Labs's short interest can also be evaluated against the total number of ProPhase Labs shares, or, against the total number of tradable ProPhase Labs shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case ProPhase Labs's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 ProPhase Labs shares in existence, roughly 10 shares are currently held short) or 0.0144% of the tradable shares (for every 100,000 tradable ProPhase Labs shares, roughly 14 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against ProPhase Labs.

Find out more about how you can short ProPhase Labs stock.

ProPhase Labs share dividends

We're not expecting ProPhase Labs to pay a dividend over the next 12 months.

Have ProPhase Labs's shares ever split?

ProPhase Labs's shares were split on a 2:1 basis on 23 January 1997. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ProPhase Labs shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ProPhase Labs shares which in turn could have impacted ProPhase Labs's share price.

ProPhase Labs share price volatility

Over the last 12 months, ProPhase Labs's shares have ranged in value from as little as $1.37 up to $11.82. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while ProPhase Labs's is 0.2394. This would suggest that ProPhase Labs's shares are less volatile than average (for this exchange).

ProPhase Labs overview

ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States. It offers a range of OTC dietary supplements, including Legendz XL for sexual health; Triple Edge XL, an energy booster and testosterone support product; and Super ProstaFlow+ a supplement to support prostate and urinary health under the TK Supplements brand. The company also provides contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; and offers COVID-19 and other respiratory pathogen panel testing services. It serves consumer products companies, as well as large national chain, regional, specialty, and local retail stores. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Doylestown, Pennsylvania.

Frequently asked questions

• What percentage of ProPhase Labs is owned by insiders or institutions?

  Currently 24.224% of ProPhase Labs shares are held by insiders and 4.132% by institutions.

• How many people work for ProPhase Labs?

  Latest data suggests 48 work at ProPhase Labs.

• When does the fiscal year end for ProPhase Labs?

  ProPhase Labs's fiscal year ends in December.

• Where is ProPhase Labs based?

  ProPhase Labs's address is: 621 North Shady Retreat Road, Doylestown, PA, United States, 18901

• What is ProPhase Labs's ISIN number?

  ProPhase Labs's international securities identification number is: US74345W1080

• What is ProPhase Labs's CUSIP number?

  ProPhase Labs's Committee on Uniform Securities Identification Procedures number is: 74345W108